These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 30973663)
21. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790 [TBL] [Abstract][Full Text] [Related]
22. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391 [TBL] [Abstract][Full Text] [Related]
23. In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. Kita K; Arai S; Nishiyama A; Taniguchi H; Fukuda K; Wang R; Yamada T; Takeuchi S; Tange S; Tajima A; Nakada M; Yasumoto K; Motoo Y; Murakami T; Yano S Cancer Med; 2017 Dec; 6(12):2972-2983. PubMed ID: 29125233 [TBL] [Abstract][Full Text] [Related]
24. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226 [TBL] [Abstract][Full Text] [Related]
25. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Rosenthal EL; Kulbersh BD; King T; Chaudhuri TR; Zinn KR Mol Cancer Ther; 2007 Apr; 6(4):1230-8. PubMed ID: 17431103 [TBL] [Abstract][Full Text] [Related]
26. In-vivo imaging of oral squamous cell carcinoma by EGFR monoclonal antibody conjugated near-infrared quantum dots in mice. Yang K; Zhang FJ; Tang H; Zhao C; Cao YA; Lv XQ; Chen D; Li YD Int J Nanomedicine; 2011; 6():1739-45. PubMed ID: 21980236 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer. Li W; Ji YH; Li CX; Liu ZY; Li N; Fang L; Chang J; Tan J World J Gastroenterol; 2016 Apr; 22(14):3758-68. PubMed ID: 27076760 [TBL] [Abstract][Full Text] [Related]
28. Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Germani A; Matrone A; Grossi V; Peserico A; Sanese P; Liuzzi M; Palermo R; Murzilli S; Campese AF; Ingravallo G; Canettieri G; Tezil T; Simone C Cancer Lett; 2014 Mar; 344(1):110-118. PubMed ID: 24215867 [TBL] [Abstract][Full Text] [Related]
29. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor. Nishimura T; Nakamura K; Yamashita S; Ikeda S; Kigure K; Minegishi T BMC Cancer; 2015 Dec; 15():957. PubMed ID: 26673416 [TBL] [Abstract][Full Text] [Related]
30. The genomic landscape of response to EGFR blockade in colorectal cancer. Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732 [TBL] [Abstract][Full Text] [Related]
31. Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12. Dong Q; Shi B; Zhou M; Gao H; Luo X; Li Z; Jiang H Front Med; 2019 Feb; 13(1):83-93. PubMed ID: 30671888 [TBL] [Abstract][Full Text] [Related]
32. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis. Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932 [TBL] [Abstract][Full Text] [Related]
33. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer. Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685 [TBL] [Abstract][Full Text] [Related]
34. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. Wen C; Chen J; Zhang D; Wang H; Che J; Qin Q; He L; Cai Z; Lin M; Lou Q; Huang L; Chen D; Iwamoto A; Ren D; Wang L; Lan P; Wang J; Liu H; Yang X Cancer Lett; 2016 Dec; 383(2):295-308. PubMed ID: 27713084 [TBL] [Abstract][Full Text] [Related]
35. Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection. Tjalma JJ; Garcia-Allende PB; Hartmans E; Terwisscha van Scheltinga AG; Boersma-van Ek W; Glatz J; Koch M; van Herwaarden YJ; Bisseling TM; Nagtegaal ID; Timmer-Bosscha H; Koornstra JJ; Karrenbeld A; Kleibeuker JH; van Dam GM; Ntziachristos V; Nagengast WB J Nucl Med; 2016 Mar; 57(3):480-5. PubMed ID: 26678613 [TBL] [Abstract][Full Text] [Related]
36. Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice. Zhang M; Jiang H; Zhang R; Jiang H; Xu H; Pan W; Gao X; Sun Z J Cell Biochem; 2019 Jun; 120(6):10239-10247. PubMed ID: 30609118 [TBL] [Abstract][Full Text] [Related]
37. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells. Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896 [TBL] [Abstract][Full Text] [Related]
38. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052 [TBL] [Abstract][Full Text] [Related]
39. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796 [TBL] [Abstract][Full Text] [Related]
40. miR-145-5p restrained cell growth, invasion, migration and tumorigenesis via modulating RHBDD1 in colorectal cancer via the EGFR-associated signaling pathway. Niu Y; Zhang J; Tong Y; Li J; Liu B Int J Biochem Cell Biol; 2019 Dec; 117():105641. PubMed ID: 31693935 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]